Phase 2 Lymphoma Trial, Recruiting NCT07097207 Sponsor: Shenzhen University General Hospital Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT07097207
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 15 and 75 years old (any gender)
  • You have been diagnosed with B-cell lymphoma that has come back or stopped responding to treatment, based on 2020 WHO guidelines
  • You are able to carry out basic daily activities, with a functional ability score of 0–2 on a standard medical scale (confirm with trial site)
  • Your doctors expect you to live for at least 3 more months
  • Tests have confirmed that your cancer cells carry a protein called CD20
  • You were not helped by, or could not tolerate, a previous treatment targeting a protein called CD19, or your cancer has low levels of CD19
  • You do not have serious heart, lung, liver, or kidney disease
  • You are able to understand and willing to sign the consent form for this trial
  • There is no medical reason why you cannot have a blood collection procedure called apheresis (confirm with trial site)
  • Your cancer has at least one measurable area that can be tracked during the trial
  • You have already received two standard courses of treatment for your condition
  • You have not received any antibody-based drug treatment in the 2 weeks before starting the cell therapy

Who may not be able to join:

  • You have a known allergy to any ingredient in the cell treatment being studied
  • Your blood test results show that certain blood cell counts are too low (white blood cells, neutrophils, lymphocytes, or platelets fall below specific levels — confirm with trial site)
  • Your liver or kidney function tests show abnormal results above certain thresholds (confirm with trial site)
  • You have been told you have moderate-to-severe heart failure, or your heart pumping function is below 50% on an ultrasound scan
  • Your blood oxygen level is below 92% while breathing normal room air
  • You had a heart attack, heart procedure, stenting, or serious heart condition within the past 12 months
  • You have severely high blood pressure that has not been controlled despite taking medication
  • You have a history of serious brain or nervous system conditions, such as a head injury, loss of consciousness, epilepsy, stroke, or bleeding in the brain
  • You have an autoimmune disease, immune deficiency, or any condition that requires you to take medicines that suppress the immune system
  • You currently have an active infection that is not under control
  • You have previously received any CAR-T cell therapy or similar genetically modified T-cell treatment
  • You received a live vaccine within 4 weeks before joining the trial
  • You have tested positive for HIV, hepatitis B, hepatitis C, or syphilis, or you are a hepatitis B carrier
  • You have a history of alcohol abuse, drug abuse, or a mental health condition
  • You have taken part in another clinical trial within the past 3 months
  • You are pregnant, breastfeeding, planning to become pregnant during the trial, or are able to have children but are unable or unwilling to use effective contraception
  • Your doctor feels there are other reasons that make this trial unsuitable for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lixin Wang, PHD, Shenzhen University General Hospital

Phone: 0755-21839999

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen University General Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

TEAEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov